JPMorgan Chase & Co. Earnings: Mixed Investor Reaction

S&P 500 (NYSE:SPY) component JPMorgan Chase & Co. (NYSE:JPM) reported net income above Wall Street’s expectations for the second quarter. J.P. Morgan Chase is a global securities, investment banking and retail banking firm with operations worldwide.

Are you well-positioned with a winning post-election portfolio?: Check out our newest CHEAT SHEET stock picks now>>

JPMorgan Chase & Co. Earnings Cheat Sheet

Results: Net income for JPMorgan Chase & Co. rose to $5.71 billion ($1.40 per share) vs. $4.26 billion ($1.02 per share) in the same quarter a year earlier. This marks a rise of 34% from the year-earlier quarter.

Actual vs. Wall St. Expectations: JPMorgan Chase & Co. beat the mean analyst estimate of $1.16 per share.

Quoting Management: Jamie Dimon, Chairman and Chief Executive Officer, commented on financial results: “The Firm reported strong performance across all our businesses in the third quarter of 2012. Revenue for the quarter was $25.9 billion, up 6% compared with the prior year, or 16% before the impact of DVA. These results reflected continued momentum in all our businesses.”

Key Stats:

The company has now topped analyst estimates for the last three quarters. It beat the mark by 43 cents in the first quarter and by 14 cents in the fourth quarter of the last fiscal year.

Looking Forward: Over the past ninety days, the average estimate for the third quarter has fallen from $1.25 per share to $1.11, indicating that analysts are growing pessisimistic about the company’s performance next quarter. The average estimate for the fiscal year is $4.62 per share, down from $5 ninety days ago.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute — click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Earnings estimates provided by Zacks)

Don’t Miss These Additional Hot Stories:

Do Dendreon and Celgene Need Treatment of Their Own?

Google to Apple: Bring It On!

Here’s Why Starbucks Moves Like a Tech Stock